Mineralys TherapeuticsMLYS
MLYS
About: Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Employees: 51
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
315% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 13
100% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 26
69% more capital invested
Capital invested by funds: $572M [Q4 2024] → $966M (+$394M) [Q1 2025]
43% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 10 (+3) [Q1 2025]
37% more funds holding
Funds holding: 108 [Q4 2024] → 148 (+40) [Q1 2025]
3.08% more ownership
Funds ownership: 93.4% [Q4 2024] → 96.48% (+3.08%) [Q1 2025]
39% less call options, than puts
Call options by funds: $6.05M | Put options by funds: $9.94M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
5%
upside
Avg. target
$29
99%
upside
High target
$42
193%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Jefferies Dennis Ding | 5%upside $15 | Hold Initiated | 11 Jun 2025 |
HC Wainwright & Co. Matthew Caufield | 193%upside $42 | Buy Reiterated | 13 May 2025 |
Financial journalist opinion
Based on 4 articles about MLYS published over the past 30 days
Neutral
GlobeNewsWire
3 weeks ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting –
Positive
Zacks Investment Research
3 weeks ago
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
GlobeNewsWire
3 weeks ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025), which will be held in Milan at the MICO Congress Center, on May 23-26, 2025.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
Seeking Alpha
1 month ago
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medical Officer Adam Levy - CFO Conference Call Participants Michael DiFiore - Evercore ISI Richard Law - Goldman Sachs Seamus Fernandez - Guggenheim Rami Katkhuda - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode.
Neutral
GlobeNewsWire
1 month ago
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Neutral
GlobeNewsWire
1 month ago
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025.
Neutral
GlobeNewsWire
1 month ago
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.
Negative
24/7 Wall Street
1 month ago
Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend
Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season.
Neutral
GlobeNewsWire
1 month ago
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression –
Charts implemented using Lightweight Charts™